Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

390
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
390
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

91
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
91
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

426
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
426
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.1K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.1K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.2K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.2K
The Micturition Reflex01:26

The Micturition Reflex

1.5K
Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selected Patients with Benign Prostatic Enlargement and Detrusor Underactivity may Benefit from Prostate Surgery: An Exploratory Study.

Urology research & practice·2026
Same author

The Interpretability of the Neurogenic Bladder Symptom Score.

Neurourology and urodynamics·2026
Same author

ThyroidPrint: Thyroid Genetic Classifier Long-Term Follow-Up of Benign Called Lesions.

Clinical endocrinology·2026
Same author

Radiation Safety Practices and Occupational Exposure Among Brazilian Urologists: A National Survey.

International braz j urol : official journal of the Brazilian Society of Urology·2026
Same author

Botulinum Toxin Type A Injections in the Bladder Wall-An Effective Treatment for Urinary Incontinence with Low Long-Term Adherence.

Toxins·2026
Same author

Cultural adaptation and validation for Brazilian portuguese of the MENTOR tool: monitoring the efficacy of neurogenic bowel treatment.

Spinal cord·2026

Related Experiment Video

Updated: Nov 5, 2025

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.2K

Current pharmacotherapy of overactive bladder.

Evgenyi I Kreydin1, Cristiano M Gomes2, Francisco Cruz3,4

  • 1Department of Urology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.

International Braz J Urol : Official Journal of the Brazilian Society of Urology
|May 18, 2021
PubMed
Summary

Overactive bladder (OAB) treatment involves antimuscarinic agents and beta-3 agonists. Individualizing therapy based on patient factors and drug profiles is crucial for managing OAB symptoms effectively.

Keywords:
Drug TherapyMuscarinic AntagonistsUrinary Bladder, Overactive

More Related Videos

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.5K
Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.5K

Related Experiment Videos

Last Updated: Nov 5, 2025

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.2K
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.5K
Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.5K

Area of Science:

  • Urology
  • Pharmacology
  • Internal Medicine

Background:

  • Overactive bladder (OAB) presents with bothersome urinary storage symptoms, affecting both sexes and significantly impacting quality of life.
  • Current pharmacological treatments for OAB include antimuscarinic agents and beta-3 agonists (mirabegron, vibegron).

Purpose of the Study:

  • To review key factors in the contemporary pharmacological management of overactive bladder.
  • To emphasize the importance of personalized treatment strategies for OAB.

Main Methods:

  • Literature review of current pharmacological treatments for OAB.
  • Analysis of drug properties, dosing, and tolerability profiles.

Main Results:

  • OAB treatment requires careful consideration of individual patient characteristics and expectations.
  • Different medications possess unique pharmacologic properties, dosing schedules, and tolerability profiles.

Conclusions:

  • Individualized medical treatment is essential for optimizing OAB management.
  • Understanding drug-specific factors is key to successful pharmacological intervention in OAB.